Home / Market News / $RGNX
fiscal.ai Corporate Catalyst Impact 85/100 ● positive

REGENXBIO Reports Third Quarter 2026 Financial Results

Nov 5, 2026, 2:12 PM UTC · Primary ticker $RGNX

REGENXBIO reported a significant year-over-year revenue decline due to patent expirations, but a litigation settlement substantially narrowed its net loss. The company also provided key operational updates on its gene therapy pipeline, including upcoming pivotal data and BLA submission plans, which are critical for future growth.

REGENXBIO's Q3 2026 results show a sharp revenue drop from $29.7M to $9.2M, primarily due to ZOLGENSMA patent expirations, which is a negative for top-line growth. However, a $38.0M litigation settlement with Sarepta Therapeutics significantly improved the bottom line, narrowing the net loss from $61.9M to $40.7M. This settlement also bolstered the company's cash position, extending its operational runway into late Q4 2027. The market will likely focus on the upcoming topline pivotal data for sura-vec in Q4 2026 and the planned BLA submission for RGX-202 in Q1 2027, as these pipeline advancements are crucial for long-term value creation and offsetting the impact of lost royalty revenue. Short-term, the mixed financial results might lead to volatility, but long-term prospects hinge on successful clinical development.

$RGNX neutral Mixed financial results, pipeline updates
$SRPT neutral Litigation settlement counterparty
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.